Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd (EMCURE) last reported results for the quarter ended Jun 2026, with sales of ₹2,580 crore and net profit of ₹292 crore. The stock last traded at ₹1,899, a market capitalisation of ₹36,025 crore, on a P/E of 35.0. Over the past 52 weeks the stock has ranged between ₹1,306 and ₹2,101. Figures are as of 6 Oct 2026 and are not real time.
Emcure Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹1,899
- Market cap
- ₹36,025 cr
- Stock P/E
- 35.0
- Book value
- ₹261
- ROE
- 20.1%
- ROCE
- 24.0%
- Dividend yield
- 0.19%
- 52w high / low
- 2101/1306
Metrics as of 6 Oct 2026. Not real time.
Track Emcure Pharmaceuticals Ltd
Cruxal reads every Emcure Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Emcure Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- 13%
- 3 Years
- 15%
- TTM
- 18%
- 10 Years
- %
- 5 Years
- 18%
- 3 Years
- 21%
- TTM
- 37%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- 35%
- 10 Years
- %
- 5 Years
- 21%
- 3 Years
- 19%
- Last Year
- 20%
Emcure Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2,580 cr, up 22.8% from ₹2,101 cr a year earlier. Net profit was ₹292 cr, up 35.8% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 | 2,363 | 2,470 | 2,580 |
| Expenses | 1,621 | 1,608 | 1,714 | 1,684 | 1,794 | 1,871 | 1,990 | 2,048 |
| Operating profit | 381 | 355 | 402 | 417 | 475 | 493 | 480 | 532 |
| OPM % | 19% | 18% | 19% | 20% | 21% | 21% | 19% | 21% |
| Other income | 36 | 4 | -6 | 0 | 3 | -36 | 14 | 2 |
| Interest | 46 | 32 | 39 | 27 | 33 | 38 | 46 | 32 |
| Depreciation | 97 | 97 | 97 | 99 | 105 | 105 | 106 | 110 |
| Profit before tax | 273 | 230 | 261 | 291 | 341 | 314 | 341 | 394 |
| Tax % | 26% | 32% | 24% | 26% | 26% | 26% | 29% | 26% |
| Net profit | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 292 |
| EPS (₹) | 10.29 | 8.11 | 9.97 | 10.92 | 12.84 | 12.16 | 12.84 | 15.50 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Emcure Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,717 | 5,049 | 5,033 | 5,855 | 5,986 | 6,658 | 7,896 | 9,204 | 9,683 |
| Operating profit | 749 | 708 | 1,216 | 1,330 | 1,182 | 1,230 | 1,469 | 1,746 | 1,980 |
| OPM % | 16% | 14% | 24% | 23% | 20% | 18% | 19% | 19% | 20% |
| Net profit | 209 | 101 | 419 | 703 | 562 | 528 | 707 | 941 | 1,019 |
| EPS (₹) | 10.79 | 4.62 | 23.15 | 36.62 | 29.42 | 27.50 | 35.96 | 48.76 | 53.34 |
TTM is the trailing twelve months to the most recent quarter.
Emcure Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 181 | 181 | 181 | 181 | 181 | 181 | 189 | 190 |
| Reserves | 1,654 | 1,731 | 2,092 | 1,807 | 2,320 | 2,771 | 4,257 | 4,760 |
| Borrowings | 2,128 | 2,327 | 2,310 | 2,217 | 2,334 | 2,335 | 1,023 | 1,521 |
| Other liabilities | 1,613 | 1,721 | 2,184 | 1,816 | 1,798 | 2,422 | 2,653 | 3,043 |
| Total liabilities | 5,577 | 5,960 | 6,768 | 6,021 | 6,634 | 7,709 | 8,122 | 9,514 |
| Fixed assets | 2,247 | 2,382 | 2,188 | 2,044 | 2,147 | 3,125 | 3,197 | 3,319 |
| CWIP | 581 | 485 | 302 | 320 | 411 | 159 | 177 | 273 |
| Investments | 0 | 0 | 0 | 25 | 25 | 318 | 95 | 20 |
| Other assets | 2,749 | 3,093 | 4,278 | 3,632 | 4,050 | 4,108 | 4,652 | 5,903 |
| Total assets | 5,577 | 5,960 | 6,768 | 6,021 | 6,634 | 7,709 | 8,122 | 9,514 |
As reported by the company. Total assets equal total liabilities by construction.
Emcure Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 444 | 500 | 704 | 768 | 747 | 1,097 | 852 | 944 |
| Cash from investing | -409 | -168 | -256 | -574 | -468 | -715 | -96 | -1,175 |
| Cash from financing | -735 | -301 | -189 | -152 | -145 | -164 | -814 | 343 |
| Net cash flow | -700 | 32 | 259 | 42 | 134 | 219 | -58 | 112 |
| Free cash flow | 39 | 362 | 571 | 349 | 345 | 801 | 475 | 400 |
| CFO / operating profit | 77% | 84% | 74% | 81% | 80% | 107% | 75% | 75% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Emcure Pharmaceuticals Ltd operating ratios
| Per year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 11% | 22% | 26% | 21% | 19% | 20% | 24% |
| Debtor days | 75 | 83 | 107 | 82 | 101 | 102 | 93 | 102 |
| Inventory days | 234 | 211 | 293 | 237 | 223 | 225 | 224 | 239 |
| Days payable | 142 | 133 | 188 | 184 | 175 | 193 | 172 | 180 |
| Cash conversion cycle | 167 | 161 | 212 | 135 | 148 | 134 | 145 | 161 |
| Working capital days | -15 | -28 | -16 | 9 | 22 | 28 | 76 | 62 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Emcure Pharmaceuticals Ltd shareholding pattern
Promoters held 77.83% at Jun 2026, broadly unchanged since Jun 2025. FIIs 4.87% and DIIs 8.46%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 78.08% | 77.94% | 77.92% | 77.92% | 77.88% | 77.87% | 77.87% | 77.83% |
| FIIs | 2.91% | 3.05% | 3.06% | 2.86% | 3.29% | 3.59% | 3.35% | 4.87% |
| DIIs | 3.96% | 3.87% | 3.44% | 2.84% | 4.36% | 6.10% | 6.10% | 8.46% |
| Public | 15.05% | 15.15% | 15.58% | 16.39% | 14.46% | 12.43% | 12.69% | 8.84% |
| No. of shareholders | 1,52,914 | 1,43,449 | 1,39,671 | 1,33,549 | 1,26,169 | 1,18,863 | 1,22,189 | 1,24,991 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Emcure Pharmaceuticals Ltd corporate filings
- Emcure Pharmaceuticals Receives Penalty Orders of Rs. 57.74 Crore from Income Tax Department for FY 2014-15 to FY 2020-21Company Updatemedium impact
Cruxal's analysis: Emcure Pharmaceuticals has disclosed that it has received orders from the Income-tax…
Read the full analysis - Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
- Emcure Pharmaceuticals Reports Strong Q1 FY27 Performance with 22.8% Revenue Growth and 36.2% PAT SurgeCompany Updatehigh impact
Cruxal's analysis: Emcure Pharmaceuticals Limited has released its Investor Presentation for September 2026…
Read the full analysis - Emcure Pharmaceuticals Ltd announces change in Board compositionCompany Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has filed an intimation under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Emcure Pharmaceuticals Limited announces successful conclusion of 45th Annual General Meeting and approval of all resolutionsAGM/EGMlow impact
Cruxal's analysis: Emcure Pharmaceuticals Limited has successfully concluded its 45th Annual General Meeting…
Read the full analysis - Emcure Pharmaceuticals Concludes 45th AGM; Approves Final Dividend of INR 3.60 per Share and Board Re-appointmentsAGM/EGMlow impact
Cruxal's analysis: Emcure Pharmaceuticals Limited has successfully concluded its 45th Annual General…
Read the full analysis - Emcure Pharmaceuticals allots 11,400 equity shares under ESOP Scheme 2013Company Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has allotted 11,400 equity shares to employees following the…
Read the full analysis - Emcure Pharmaceuticals Ltd: Dispatch of communication to shareholders with unregistered e-mail addressesCompany Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has initiated the dispatch of letters to shareholders whose e-mail…
Read the full analysis - Emcure Pharmaceuticals schedules investor meet for September 04, 2026Company Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has issued an intimation regarding a scheduled investor meet to be…
Read the full analysis - Emcure Pharmaceuticals Limited Receives Reaffirmation of CARE AA; Stable / CARE A1+ Credit Ratings on Bank FacilitiesCompany Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals Limited has received a reaffirmation of its credit ratings from…
Read the full analysis - Emcure Pharmaceuticals Ltd announces 45th Annual General Meeting and e-voting detailsCompany Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has published a newspaper advertisement regarding the notice of…
Read the full analysis - Emcure Pharmaceuticals Ltd files Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Emcure Pharmaceuticals has submitted its Business Responsibility and Sustainability…
Read the full analysis - Emcure Pharmaceuticals Limited Announces 45th AGM and Releases Annual Report for FY 2025-26AGM/EGMhigh impact
Cruxal's analysis: Emcure Pharmaceuticals Limited has announced its 45th Annual General Meeting (AGM)…
Read the full analysis - Emcure Pharmaceuticals Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Emcure Pharmaceuticals has filed its Annual Report for the financial year 2025-26, dated…
Read the full analysis - Emcure Pharmaceuticals allots 19,100 equity shares under ESOP 2013 schemeCompany Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has allotted 19,100 equity shares to employees following the…
Read the full analysis - Emcure Pharmaceuticals Reports Strong Q1 FY27 Results with 22.8% Revenue Growth and Strategic Consolidation of GennovaCompany Updatehigh impact
Cruxal's analysis: Emcure Pharmaceuticals Limited delivered a robust Q1 FY27 performance, with revenue from…
Read the full analysis - Emcure Pharmaceuticals provides update on USFDA inspection at Sanand facilityCompany Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has issued a regulatory intimation regarding a USFDA inspection at…
Read the full analysis - Emcure Pharmaceuticals schedules analyst and investor meeting for September 22, 2026Company Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has announced an analyst and investor meeting scheduled for…
Read the full analysis - Emcure Pharmaceuticals schedules analyst and investor meeting for September 17, 2026Company Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has announced an analyst and investor meeting scheduled for…
Read the full analysis - Emcure Pharmaceuticals schedules analyst and investor meeting for September 01, 2026Company Updatelow impact
Cruxal's analysis: Emcure Pharmaceuticals has announced an analyst and investor meeting scheduled for…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.